Praxis Investment Management Inc. Increases Stock Position in Veeva Systems Inc. $VEEV

Praxis Investment Management Inc. lifted its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 26.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,920 shares of the technology company’s stock after acquiring an additional 830 shares during the period. Praxis Investment Management Inc.’s holdings in Veeva Systems were worth $1,129,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of VEEV. Nuveen LLC purchased a new position in Veeva Systems in the 1st quarter valued at $365,684,000. Price T Rowe Associates Inc. MD grew its position in Veeva Systems by 20.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after buying an additional 689,700 shares during the last quarter. Linonia Partnership LP grew its position in Veeva Systems by 52.7% in the 1st quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock valued at $425,402,000 after buying an additional 633,585 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Veeva Systems by 48.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock valued at $416,918,000 after buying an additional 585,785 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in Veeva Systems by 10.7% in the 1st quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock valued at $1,273,884,000 after buying an additional 532,269 shares during the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Veeva Systems

In related news, SVP Jonathan Faddis sold 14,595 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $300.00, for a total value of $4,378,500.00. Following the completion of the transaction, the senior vice president owned 8,588 shares of the company’s stock, valued at approximately $2,576,400. The trade was a 62.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the transaction, the insider directly owned 25,325 shares of the company’s stock, valued at $7,765,151.50. The trade was a 19.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,665 shares of company stock valued at $7,438,000 in the last 90 days. 10.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on VEEV. Citigroup lifted their price objective on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Piper Sandler lifted their price objective on shares of Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. BTIG Research restated a “buy” rating and set a $340.00 target price on shares of Veeva Systems in a research report on Friday. Canaccord Genuity Group boosted their target price on shares of Veeva Systems from $270.00 to $300.00 and gave the stock a “hold” rating in a research report on Thursday, August 28th. Finally, JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $290.00 to $330.00 in a research report on Monday, September 8th. Seventeen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

Veeva Systems Stock Down 3.0%

NYSE:VEEV opened at $283.96 on Friday. The company has a market capitalization of $46.54 billion, a PE ratio of 58.31, a price-to-earnings-growth ratio of 2.26 and a beta of 0.98. Veeva Systems Inc. has a 52-week low of $201.54 and a 52-week high of $310.50. The stock has a fifty day simple moving average of $283.44 and a 200-day simple moving average of $266.73.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). The firm had revenue of $789.08 million for the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, equities analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.